Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Long-Term Investments: 2017-2024

Historic Long-Term Investments for Arcus Biosciences (RCUS) over the last 7 years, with Dec 2024 value amounting to $14.0 million.

  • Arcus Biosciences' Long-Term Investments rose 400.00% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 400.00%. This contributed to the annual value of $14.0 million for FY2024, which is 86.92% down from last year.
  • Latest data reveals that Arcus Biosciences reported Long-Term Investments of $14.0 million as of FY2024, which was down 86.92% from $107.0 million recorded in FY2023.
  • Arcus Biosciences' 5-year Long-Term Investments high stood at $182.0 million for FY2021, and its period low was $6.4 million during FY2020.
  • Its 3-year average for Long-Term Investments is $83.3 million, with a median of $107.0 million in 2023.
  • In the last 5 years, Arcus Biosciences' Long-Term Investments surged by 2,726.09% in 2021 and then crashed by 86.92% in 2024.
  • Arcus Biosciences' Long-Term Investments (Yearly) stood at $6.4 million in 2020, then spiked by 2,726.09% to $182.0 million in 2021, then dropped by 29.12% to $129.0 million in 2022, then declined by 17.05% to $107.0 million in 2023, then crashed by 86.92% to $14.0 million in 2024.